Avid Bioservices Inc (CDMO)

[cheynew]

What's up with this:

Additionally, Peregrine and Affitech have agreed to modify the terms under their research collaboration agreement to eliminate Affitech's future obligations for the development of new antibody targets, in exchange for reduced future license fees, milestone payments and royalty obligations due from Peregrine for existing antibody targets. The collaboration has generated several fully human antibodies, including AT001/r84; PGN 635, an antibody being evaluated as part of Peregrine's government contract; and other antibodies in preclinical evaluation for the treatment of a broad range of cancer and infectious diseases indications.